Earle Burgess: We finally have evidence that a triplicate regimen in bladder cancer is better than chemo alone

Earle Burgess, Chief, Genitourinary Oncology Section at Atrium Health, Levine Cancer Institute, made the following post on LinkedIn:

“Gemcitabine (Gem) + Cisplatin (Cis) + Nivolumab (Nivo) is better than Gem + Cis alone in advanced urothelial cancer.

We finally have evidence that a triplicate regimen in bladder cancer is better than chemo alone: the CheckMate 901 study.

Never mind that chemo + pembrolizumab or + atezolizumab, both immune checkpoint inhibitors (ICI) similar to nivolumab, were really no better than chemo alone.

What’s special about Nivo that we finally got a positive chemo + ICI trial?

Let’s take a look at the CM901 trial to find out….”

Source: Earle Burgess/LinkedIn